Journal
LUNG CANCER
Volume 69, Issue 3, Pages 337-340Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2009.11.019
Keywords
Lung cancer; Erlotinib; Bevacizumab; Serum biomarker; Proteomics; Personalized therapy
Categories
Funding
- Vanderbilt Lung Cancer [P50 CA-90949, UO1 CA114771]
Ask authors/readers for more resources
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat (R)) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat (R) could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available